News 30.05.18

New at Pivot Park – GlycoMScan

Recently GlycoMScan has opened their company’s doors in the van Leeuwenhoek building’s basement. GlycoMScan offers services in mass spectrometry, from screening of small molecules to absolute quantification in complex biological matrices.

Read more
News 29.05.18

New Dutch Q fever test comes out on top in Australian research

The Q-detect™ test, developed by the Dutch Innatoss, turns out to be the best test by far for Q fever screening. The results were presented at the European microbiology conference ECCMID in Madrid.

Read more
News 23.05.18

Glycostem moves into new lab, production and HQ facility

Glycostem relocated to its new facilities at Pivot Park, Oss, Netherlands. Collectively comprising nearly 500 square meters, the premises include the company’s stateof-the-art laboratory, production facility and administrative HQ.

Read more
News 26.03.18

NTRC expands SynergyFinder™ platform with triple combination testing

NTRC’s SynergyFinder™ platform allows parallel in vitro screening of combinations and distinguishes additive from synergistic effects.

Read more
News 22.03.18

Prexton Therapeutics acquired by Lundbeck

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced March 16th the signing of a definitive agreement in which Lundbeck will acquire Prexton.

Read more
News 14.03.18

Ardena acquires ChemConnection adding API expertise

Contract development and manufacturing organisation (CDMO) Ardena has acquired ChemConnection.

Read more
News 13.03.18

InProcess-LSP ontvangt financiering voor nieuwe testtechniek ‘nanomedicijnen’

Life sciences-start-up InProcess-LSP haalt een investering op bij de Brabantse Ontwikkelings Maatschappij (BOM) voor de verdere ontwikkeling van de NanoFlowSizer.

Read more
News 07.03.18

Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors

Aduro Biotech announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase I clinical trial of its anti-CD27 antibody.

Read more
News 01.03.18

Brigitte Drees nieuwe directeur Pivot Park

Brigitte Drees volgt Mirjam Mol-Arts op, welke 1 januari afscheid nam van het Pivot Park.

Read more